Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium
Authors
Keywords
-
Journal
International Journal of Clinical Oncology
Volume 27, Issue 8, Pages 1348-1355
Publisher
Springer Science and Business Media LLC
Online
2022-05-21
DOI
10.1007/s10147-022-02183-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide
- (2022) Alexander Pan et al. JOURNAL OF UROLOGY
- Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events
- (2022) MICHIE KATSUTA et al. ANTICANCER RESEARCH
- Impact of body size on skin‐related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study
- (2022) Daichi Sasaki et al. INTERNATIONAL JOURNAL OF UROLOGY
- Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model
- (2020) An Van den Bergh et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer
- (2020) Carlos Perez-Ruixo et al. CLINICAL CANCER RESEARCH
- Apalutamide and Overall Survival in Prostate Cancer
- (2020) Matthew R. Smith et al. EUROPEAN UROLOGY
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- (2020) Philip Cornford et al. EUROPEAN UROLOGY
- Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
- (2020) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
- (2020) Hiroji Uemura et al. BMC Urology
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
- (2019) Tomohiro Tsuchiya et al. International Journal of Clinical Oncology
- Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model
- (2019) Changhua Ji et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment
- (2016) Hiroji Uemura et al. BMC Urology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More